Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A superficial, epithelial Herpesvirus hominis infection of the cornea, characterized by the presence of small vesicles which may break down and coalesce to form dendritic ulcers (keratitis, dendritic). (Dictionary of Visual Science, 3d ed)
Biomarker and diagnostic research for herpes simplex virus keratitis has been reported in the published literature.
No approved treatments are currently available for herpes simplex virus keratitis. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for herpes simplex virus keratitis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for herpes simplex virus keratitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
No clinical trials have been registered for herpes simplex virus keratitis.
95 publications have been identified in PubMed for herpes simplex virus keratitis. Research spans Basic Science / Preclinical (39%), Case Report / Case Series (17%), and Gene Therapy / Novel Therapeutics (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 37 | 39% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:59 AM UTC
European rare disease database
Designated
Exclusivity End |
|---|
Designation Status |
|---|
acyclovir | acyclovir | GlaxoSmithKline | 2010 | — | Withdrawn |
Gene therapy approaches for herpes simplex virus keratitis have been reported in the published literature.
View trials for herpes simplex virus keratitis
Patient case studies
16 |
17% |
New treatment approaches | 15 | 16% |
Research summaries | 13 | 14% |
Disease patterns and progression | 10 | 11% |
Testing and diagnosis research | 3 | 3% |
Clinical study results | 1 | 1% |
Arya D (2026). [PMID: 42189879](https://pubmed.ncbi.nlm.nih.gov/42189879/). *PLoS Pathog*. [Basic Science / Preclinical]
Chen Z (2026). [PMID: 41651440](https://pubmed.ncbi.nlm.nih.gov/41651440/). *Exp Eye Res*. [Diagnostic / Biomarker]
Jbara-Agbaria D (2026). [PMID: 41318007](https://pubmed.ncbi.nlm.nih.gov/41318007/). *Eur J Pharm Sci*. [Gene Therapy / Novel Therapeutics]
Nunn J (2026). [PMID: 41531120](https://pubmed.ncbi.nlm.nih.gov/41531120/). *Transpl Infect Dis*. [Basic Science / Preclinical]
Randag AC (2026). [PMID: 41786502](https://pubmed.ncbi.nlm.nih.gov/41786502/). *Br J Ophthalmol*. [Review / Meta-Analysis]
Borase H (2026). [PMID: 41921851](https://pubmed.ncbi.nlm.nih.gov/41921851/). *Exp Eye Res*. [Basic Science / Preclinical]
Luo J (2026). [PMID: 41628806](https://pubmed.ncbi.nlm.nih.gov/41628806/). *Exp Eye Res*. [Basic Science / Preclinical]
Tiwari V (2026). [PMID: 41594640](https://pubmed.ncbi.nlm.nih.gov/41594640/). *Biomolecules*. [Review / Meta-Analysis]
Elste J (2026). [PMID: 41751906](https://pubmed.ncbi.nlm.nih.gov/41751906/). *Int J Mol Sci*. [Basic Science / Preclinical]
Akinsiku S (2026). [PMID: 41754438](https://pubmed.ncbi.nlm.nih.gov/41754438/). *Pathogens*. [Review / Meta-Analysis]
AI-curated news mentioning herpes simplex virus keratitis
Updated Sep 18, 2026
A case report highlights a multifocal mucocutaneous herpes simplex virus type 1 infection occurring in a young adult following seasonal influenza vaccination. This observation raises questions about potential vaccine-related immune responses in individuals without known immunocompromising conditions.
A case report highlights the occurrence of herpes simplex virus type 1 uveitis in the fellow eye following intravitreal administration of bevacizumab. This finding may prompt further investigation into the safety profile of bevacizumab in patients with a history of herpes virus infections.
A recent publication discusses the fundamentals of neonatal herpes simplex virus, highlighting its transmission, clinical manifestations, and management strategies. This research contributes to the understanding of this rare viral infection in newborns.